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stage II, 27.9% (n=6 295) at stage III, and 39.0% (n=8 820) at stage IV. There were no
information regarding stage for 14.0% (n=3 171) of cases. Mortality/ incidence ratio
has improved from 0.88 in 1980 to 0.76 in 2007. First year’s lethality increased from
55.1% in 1980 to 67.2% in 2007. Five year observed survival of patients with gastric
cancer decreased from 22.3% for patients diagnosed in 1980 to 14.3% for patients
diagnosed in 2004. The age-standardized incidence rates (European standard)
decreased from 36.9 per 100 000 population in 1980 to 22.1 in 2007, but mortality –
from 31.8 in 1980 to 16.5 in 2007. The same trend was observed if analyzed by gender.
Conclusions: Incidence of gastric cancer and its caused mortality has a trend to
decrease in Latvia. However it is still considerably higher than on average in European
Region or in European Union. The proportion of late diagnosed cases is high and
indicates on necessity to improve early diagnostics and to perform more effective
actions against cancer.
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Background: Gastric Cancer (GC) as the third most common malignancy in Iran,
accounts for50% of all GI cancers who cause 55% of all cancer-related deaths in Iran.
The rates of GC reported from Ardabil Province are among the highest in the world.
Upper gastrointestinal cancer accounts for more than 50% of all cancer deaths in this
area. Codon 72 polymorphism of the tumor suppressor gene TP53 has been associated
with a higher risk in the development of several types of cancer. The polymorphism
results in a variant protein with either an arginine (CGC) or a proline residue (CCC).
We aimed analyze the association of the TP53 codon 72 polymorphism with the risk of
developing gastric cancer in a high-risk population around the world.
Methods: We enrolled 100 patients with mean age 65.9 Yrs. affected with primary GC
and same age- and sex- matched healthy control participants. The analysis has been
carried out by PCR-RFLP on DNA extractions from peripheral blood.
Results: In the case group, the genotype was 16.1%, 42.5%, and 41.4% for Arg/Arg,
Arg/Pro, and Pro/Pro, respectively. And for controls were 18.5%, 40.2%, and 41.4%. In
comparing case and control group, any significant difference has been found.
Conclusion: Because of high frequency of GC in our province, the investigations about
the role of genetic susceptibilities for GC are very important. In spite of finding no
relationship between P53 polymorphisms, studying other genetic variations is
recommended.
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Background: A family history of gastric cancer is considered to be a possible etiologic
factor. This study was designed to analyze the clinicopathological characteristics of
gastric cancer patients with a family history of gastric cancer and to aid in planning
diagnostic and therapeutic approaches in such patients
Method: From January 1997 to July 2001, 611 gastric cancer patients who underwent
surgery at our center were enrolled in this study. We divided two groups of patients
with a family history of cancer and patients without a family history of cancer. We
compared age, location of lesion, number of lesion, grossly and microscopically
histological type, TNM stage, extent of gastrectomy and CEA level between two groups.
Results: The highest range of group with a family history of gastric cancer were more
younger than that of the patients without a family history of cancer. (p=0.05) The
solitary lesion of gastric cancer was not statistically significant difference in two groups.
But, multiple primary lesions (more than 2) was more common with family history
(p=0.05). The positive family history group had higher incidence compared to negative
gastric cancer family history in EGC IIc type. (16.7% vs 6.9%)(p=0.032). There were no
statistically significant difference in the location between the two groups. In the
evaluation by histologic distribution, ’signet ring cell type’ showed the highest
distribution in the group with family history (19 cases, 31.7%) while ’poorly
differentiated type’ showed the highest distribution in the group without family cancer
(214 cases, 39.3%); however, the difference showed no statistical significance (p=0.11).
There were no statistically significant difference in the TNM stage and extent of
gastrectomy in the two groups. 9 patients (14.5%) showed CEA elevation of more than
5 ng/ml in the group with family history compared to 138 patients (25.1%) in the
group without family history. 53 patients (85.5%) showed CEA elevation of less than 5
ng/ml in the group with family history compared to 411 patients (74.9%) in the group
without family history. There was no clinically significant difference between two
groups. 5-years survival rate in the group with family history was 55.0% compared to
60.5% in the group without family history. There was no statistically significant
difference between two groups.
Conclusions: There was no statistically significant difference in sex, age distribution,
location of cancer lesions, extent of gastrectomy, CEA level and 5-year survival rate
depend-ing on the presence of family history of gastric cancer in patients. Only gross
differentiation showed statistically significant difference, and multiple primary lesions
(more than 2) was more common in the group with family history.
P-0027 SERUM PEPSINOGEN LEVELS IN DEVELOPING GASTRIC
CANCER SCREENING APPROACHES FOR IRANIAN HIGH RISK
POPULATIONS
Yeganeh Talebkhan1, Fatemeh Ebrahimzadeh1, Ameneh Farjaddoost1, Akbar
Oghalaie1, Arman Morakabati3, Azin Nahvijou2, Marjan Mohammadi1
1Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran, 2Cancer
Research Center, Tehran University of Medical Sciences, Tehran, Iran, 3Qom
University of Medical Sciences, School of Medicine, Qom, Iran
Background: Besides dramatic decrease of gastric cancer (GC) incidence in developed
countries during recent years, it has been repeatedly reported as the second most
prevalent cancer with the highest mortality rate in developing countries like Iran.
Several studies have shown that serum pepsinogen (PG) levels can be used to screen
subjects at high risk of GC development. The aim of this study was to evaluate the role
of serum pepsinogen I and II levels as two potential markers for non-invasive screening
of high risk populations.
Materials and Methods: 382 GC patients (cases), 626 non ulcer dyspeptic patients
(NUD) and 179 healthy blood donors were enrolled as hospital and population based
controls, respectively. Fasting blood samples were taken for measuring serum PG I, PG
II by commercially available ELISA tests according to the manufacturer’s instructions.
GC cases were categorized according to tumor subsite and subtype. PMN/neutrophil
infiltrations, gastric atrophic and intestinal metaplastic changes were graded according
to the newly developed OLGA staging system.
Results: Serum PG I, II levels, I/II ratio were significantly different among cases and
controls (P<0.05). Multiple logistic regression analyses showed that low PG I/PG II ratio
(£3.0) increases the risk of GC development by 5.2-7.7, which is mostly owed to cardia
than non-cardia GC when compared to population based controls (OR=4.7; 95%CI=2.0
-10.7 vs. OR=3.6; 95%CI=1.5-8.5) and hospital based controls (OR=4.3; 95%CI=2.2-8.4
vs. OR=3.3; 95%CI=1.7-6.7). When cases were stratified according to GC subtypes, low
PG I/II ratio also presented a risk for GC development, which was more pronounced for
intestinal than diffuse tumor subtypes, when healthy (OR=5.6; 95%CI=2.43-12.8 vs.
OR=2.9; 95%CI=1.1-7.5) and NUD (OR=5.15; 95%CI=2.7-10.0 vs. OR=2.7;
95%CI=1.9-6.04) controls were selected as the reference groups. Microscopic grading of
inflammation in gastric biopsies among NUD group demonstrated that PGI/II ratio is
significantly (P<0.001) lower in those who suffer from severe grades of gastric
inflammation (grade 3: 10.6±15.4; grade 4: 19±31.7) in comparison with those with lower
grades of inflammation (grade 0: 15.1±15.2; grade 1: 10.5±5.15; grade 2: 11.8±11.43).
Conclusion: The statistically significant risk impact of low serum PGI/II ratio on GC
development in both subsites and subtypes, recommends the application of this non-
invasive assay in population screening approaches and identification of high risk
subjects for follow-up endoscopy and early detection of malignant lesions.
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Introduction: Gastric cancer is a multi-factorial disease resulting from interaction
between host, pathogen and environmental factors. It has been speculated that
geographic variations in gastric cancer risk may be partly due to single nucleotide gene
polymorphisms in genes causing susceptibility to cancer. The aim of this study was to
assess the impact of a number of gene polymorphisms and gastric cancer risk in an
Iranian population.
Materials and Methods: We evaluated the joint effect of several single nucleotide
polymorphisms (SNPs) on gastric cancer development and its subcategories. Ten gene
polymorphisms involved in inflammation (interleukins: IL-1b, IL-1RN, IL-8, IL-10),
detoxification of carcinogens (glutathione s-transferases M1, T1: GSTM1, GSTT1),
folate metabolism (methylenetetrahyrofolate reductase: MTHFR), and intercellular
adhesion (E-cadherin: CDH-1) were evaluated by by CTPP-PCR and PCR-RFLP on
genomic DNA extracted from white blood cells. In this study, 98 patients diagnosed
with gastric cancer (GC) were compared with 140 healthy individuals using logistic
regression analysis, calculating odds ratios (ORs) and 95% confidence intervals (95%
CI) by SPSS 18.0 statistics software.
Results:We observed that individuals with 5 or more SNPs were at more than two fold
increased risk of gastric cancer (OR: 2.255, 95% CI: 1.006-5.055, P=0.048) which was
further enhanced in the older (>50 years) age stratum (OR: 3.632, 95% CI (1.324-
9.965), P=0.012). In addition, stratification based on GC subsites demonstrated that
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